What question did this study set out to answer?

To evaluate the impact of somatic mutations at diagnosis on treatment outcomes in chronic phase CML patients receiving imatinib.

December 8, 2025BloodOpen Access

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

View Full Paper

Ask AI

Bookmark

Authors

JRJenny Rinke RSRwth Stuckey MYMohamed A. Yassin

Discussion

Member takes

Overview

Analysis reveals somatic mutations at diagnosis affect progression-free survival in chronic phase CML patients treated with imatinib, indicating treatment management implications.

Key Points

To evaluate the impact of somatic mutations at diagnosis on treatment outcomes in chronic phase CML patients receiving imatinib.
Analyzed genomic data from 468 chronic phase CML patients treated with imatinib.
Used next-generation sequencing to identify somatic mutations in myeloid genes.
Kaplan–Meier curves estimated progression-free survival (PFS) and failure-free survival (FFS).
20.5% of patients had pathogenic variants at diagnosis, primarily ASXL1 mutations.
Five-year PFS for patients with pathogenic variants was 76.3%, compared to 83.1% for those without variants.
Five-year FFS was significantly lower in patients with pathogenic variants (43.8% vs 65.2%).

Cite This Study

Rinke et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd9 https://doi.org/10.1182/blood-2025-75

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

View Full Paper

Ask AI

Bookmark

Authors

JRJenny Rinke RSRwth Stuckey MYMohamed A. Yassin

Discussion

Member takes

Overview

Analysis reveals somatic mutations at diagnosis affect progression-free survival in chronic phase CML patients treated with imatinib, indicating treatment management implications.

Key Points

To evaluate the impact of somatic mutations at diagnosis on treatment outcomes in chronic phase CML patients receiving imatinib.
Analyzed genomic data from 468 chronic phase CML patients treated with imatinib.
Used next-generation sequencing to identify somatic mutations in myeloid genes.
Kaplan–Meier curves estimated progression-free survival (PFS) and failure-free survival (FFS).
20.5% of patients had pathogenic variants at diagnosis, primarily ASXL1 mutations.
Five-year PFS for patients with pathogenic variants was 76.3%, compared to 83.1% for those without variants.
Five-year FFS was significantly lower in patients with pathogenic variants (43.8% vs 65.2%).

Cite This Study

Rinke et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd9 https://doi.org/10.1182/blood-2025-75

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark